Ocular Therapeutix, Inc.
DE ˙ DB ˙ US67576A1007
7,15 € ↑0,25 (3,62%)
2026-06-04
DEL PRIS
SecurityDE:0OT / Ocular Therapeutix, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership1,536,779 shares
Latest Disclosed Value $ 13,016,517
Invesco Ltd. reports 71.58% increase in ownership of 0OT / Ocular Therapeutix, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 1,536,779 shares of Ocular Therapeutix, Inc. (DE:0OT) valued at $10,210,360 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 895,687 shares of Ocular Therapeutix, Inc.. This represents a change in shares of 71.58% during the quarter. The current value of the position is $10,987,970 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F OCULAR THERAPEUTIX COM 67576A100 1,536,779 641,092 71.58 13,017 19.71 0.0002
2026-02-19 2025-12-31 13F OCULAR THERAPEUTIX COM 67576A100 895,687 -148,209 -14.20 10,874 -10.90 0.0017
2025-11-13 2025-09-30 13F OCULAR THERAPEUTIX COM 67576A100 1,043,896 -494,950 -32.16 12,203 -14.54 0.0019
2025-08-13 2025-06-30 13F OCULAR THERAPEUTIX COM 67576A100 1,538,846 734,017 91.20 14,280 142.07 0.0024
2025-05-12 2025-03-31 13F OCULAR THERAPEUTIX COM 67576A100 804,829 -85,217 -9.57 5,899 -22.38 0.0011
2025-02-13 2024-12-31 13F OCULAR THERAPEUTIX COM 67576A100 890,046 134,573 17.81 7,601 15.64 0.0014
2024-11-12 2024-09-30 13F OCULAR THERAPEUTIX COM 67576A100 755,473 709,573 1,545.91 6,573 1,999.68 0.0013
2024-08-13 2024-06-30 13F OCULAR THERAPEUTIX COM 67576A100 45,900 -726,466 -94.06 314 -95.55 0.0001
2024-05-14 2024-03-31 13F OCULAR THERAPEUTIX COM 67576A100 772,366 551,339 249.44 7,029 613.50 0.0015
2024-02-13 2023-12-31 13F OCULAR THERAPEUTIX COM 67576A100 221,027 -28,912 -11.57 986 25.64 0.0002
2023-11-13 2023-09-30 13F OCULAR THERAPEUTIX COM 67576A100 249,939 71,390 39.98 785 -14.88 0.0002
2023-08-11 2023-06-30 13F OCULAR THERAPEUTIX COM 67576A100 178,549 9,397 5.56 921 3.37 0.0002
2023-05-12 2023-03-31 13F OCULAR THERAPEUTIX COM 67576A100 169,152 -96,621 -36.35 891 19.44 0.0002
2023-02-13 2022-12-31 13F OCULAR THERAPEUTIX COM 67576A100 265,773 129,788 95.44 747 32.27 0.0002
2022-11-14 2022-09-30 13F OCULAR THERAPEUTIX COM 67576A100 135,985 -36,958 -21.37 564 -18.85 0.0002
2022-08-15 2022-06-30 13F OCULAR THERAPEUTIX COM 67576A100 172,943 12,619 7.87 695 -12.47 0.0002
2022-05-16 2022-03-31 13F OCULAR THERAPEUTIX COM 67576A100 160,324 23,225 16.94 794 -16.86 0.0002
2022-02-14 2021-12-31 13F OCULAR THERAPEUTIX COM 67576A100 137,099 30,658 28.80 955 -10.24 0.0002
2021-11-15 2021-09-30 13F OCULAR THERAPEUTIX COM 67576A100 106,441 17,923 20.25 1,064 -15.22 0.0003
2021-08-17 2021-06-30 13F OCULAR THERAPEUTIX COM 67576A100 88,518 26,146 41.92 1,255 22.56 0.0003
2021-05-17 2021-03-31 13F OCULAR THERAPEUTIX COM 67576A100 62,372 -938,524 -93.77 1,024 -95.06 0.0003
2021-02-16 2020-12-31 13F OCULAR THERAPEUTIX COM 67576A100 1,000,896 811,055 427.23 20,718 1,333.77 0.0060
2020-11-16 2020-09-30 13F OCULAR THERAPEUTIX COM 67576A100 189,841 -412,832 -68.50 1,445 -71.22 0.0005
2020-08-14 2020-06-30 13F OCULAR THERAPEUTIX COM 67576A100 602,673 463,694 333.64 5,020 629.65 0.0018
2020-05-15 2020-03-31 13F OCULAR THERAPEUTIX COM 67576A100 138,979 138,979 688 0.0003
2019-08-14 2019-06-30 13F/A-1 OCULAR THERAPEUTIX COM 67576A100 0 -286,118 -100.00 0 -100.00
2019-05-15 2019-03-31 13F OCULAR THERAPEUTIX COM 67576A100 286,118 68,470 31.46 1,136 31.18 0.0004
2019-02-14 2018-12-31 13F OCULAR THERAPEUTIX COM 67576A100 217,648 182,510 519.41 866 257.85 0.0003
2018-11-14 2018-09-30 13F OCULAR THERAPEUTIX COM 67576A100 35,138 8,955 34.20 242 36.72 0.0001
2018-08-14 2018-06-30 13F OCULAR THERAPEUTIX COM 67576A100 26,183 26,183 177 0.0001
2015-11-16 2015-09-30 13F OCULAR THERAPEUTIX COMMON 67576A100 0 -2,767 -100.00 0 -100.00
2015-08-14 2015-06-30 13F OCULAR THERAPEUTIX COMMON 67576A100 2,767 2,767 58 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.